In silico and in vitro analysis of lncRNA XIST reveals a panel of possible lung cancer regulators and a five-gene diagnostic signature by Katopodis, P et al.
cancers
Article
In Silico and In Vitro Analysis of lncRNA XIST
Reveals a Panel of Possible Lung Cancer Regulators
and a Five-Gene Diagnostic Signature
Periklis Katopodis 1,2 , Qiduo Dong 1, Heerni Halai 1, Cristian I. Fratila 1, Andreas Polychronis 3,
Vladimir Anikin 1,2,4, Cristina Sisu 1 and Emmanouil Karteris 1,2,*
1 Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK;
periklis.katopodis@brunel.ac.uk (P.K.); 1706896@brunel.ac.uk (Q.D.); 1710660@brunel.ac.uk (H.H.);
1607992@brunel.ac.uk (C.I.F.); v.anikin@rbht.nhs.uk (V.A.); cristina.sisu@brunel.ac.uk (C.S.)
2 Division of Thoracic Surgery, The Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital,
London UB9 6JH, UK
3 Mount Vernon Cancer Centre, Northwood HA6 2RN, UK; andreas.polychronis@nhs.net
4 Department of Oncology and Reconstructive Surgery, Sechenov First Moscow State Medical University,
119146 Moscow, Russia
* Correspondence: emmanouil.karteris@brunel.ac.uk; Tel.: +44-18-9526-5892
Received: 30 October 2020; Accepted: 19 November 2020; Published: 24 November 2020 
Simple Summary: Long non-coding RNAs (lncRNA) have been associated with a number of diseases
including cancer. A well-studied lncRNA called XIST (X-inactive specific transcript) acts as a major
effector of the X-inactivation process. It is expressed on the inactive X chromosome providing a dosage
equivalence between males and females. Recently XIST has been implicated in the development of
lung cancer. Using a bioinformatics approach, we demonstrate the XIST is over-expressed in female
patients compared to males. When XIST gene was silenced in two different cell lines (of male and
female origin), a number of genes were differentially expressed; playing a role in signal transduction
pathways, energy balance and metabolism, thus providing a better insight of the role of this lncRNA in
cancer. Finally, we showed that expression of XIST with another 4 genes provided a strong diagnostic
potential to discriminate lung cancer from healthy controls.
Abstract: Long non-coding RNAs (lncRNAs) perform a wide functional repertoire of roles in cell
biology, ranging from RNA editing to gene regulation, as well as tumour genesis and tumour
progression. The lncRNA X-inactive specific transcript (XIST) is involved in the aetiopathogenesis of
non-small cell lung cancer (NSCLC). However, its role at the molecular level is not fully elucidated.
The expression of XIST and co-regulated genes TSIX, hnRNPu, Bcl-2, and BRCA1 analyses in lung
cancer (LC) and controls were performed in silico. Differentially expressed genes (DEGs) were
determined using RNA-seq in H1975 and A549 NSCLC cell lines following siRNA for XIST. XIST
exhibited sexual dimorphism, being up-regulated in females compared to males in both control and
LC patient cohorts. RNA-seq revealed 944 and 751 DEGs for A549 and H1975 cell lines, respectively.
These DEGs are involved in signal transduction, cell communication, energy pathways, and nucleic
acid metabolism. XIST expression associated with TSIX, hnRNPu, Bcl-2, and BRCA1 provided a
strong collective feature to discriminate between controls and LC, implying a diagnostic potential.
There is a much more complex role for XIST in lung cancer. Further studies should concentrate
on sex-specific changes and investigate the signalling pathways of the DEGs following silencing of
this lncRNA.
Keywords: XIST; x-inactivation center; NSCLC; lncRNA; TCGA; GTEX; RNA-seq; lung
cancer; bioinformatics
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1. Introduction
The large-scale genome sequencing studies of the last decade have documented the pervasive
transcription of almost 90% of the human genome [1], with 98% of the transcriptome consisting of
long non-coding RNAs (lncRNAs) [2]. However, despite these efforts, our current understanding of
lncRNAs’ complex biology is still limited. Long non-coding RNAs are a class of RNA molecules that
do not encode proteins and range in length from 200 nucleotides to 100 kilobases [3]. Previous analyses
have pointed to a wide range of functions for lncRNAs in developmental and cellular processes,
including gene expression, chromatin remodeling and modification, splicing, editing, translation and
degradation of the RNA, and gene silencing with endogenous small interfering RNA (siRNA) [4–6].
LncRNAs were found to be expressed in a variety of diseases including cancer suggesting potential
roles as biomarkers or even therapeutic targets. Studies have identified key lncRNAs as regulators
of oncogenes and tumour suppressors such as PTEN and KRAS [7–9]. Other lncRNAs were shown
to be important for genomic imprinting, and for regulating epigenetic procedures. This is the case
for lncRNA X-inactive specific transcript (XIST) that inactivates one of the two X chromosomes in
females [10–12].
In literature, XIST is described interchangeably as either a lncRNA or a pseudogene and acts
as a major effector in the X chromosome inactivation process. It is expressed only on the inactive
X chromosome providing a dosage equivalence between males and females (reviewed in [10,13]). XIST
was the first non-coding gene identified in the X inactivation center (XIC) region [14]. The expression
of this lncRNA is the essential step for the initiation of the X inactivation. XIST is transcribed, spliced,
and polyadenylated resulting in an mRNA. However, no protein products have ever been observed.
XIST is coating and inactivates one of the X chromosomes (Figure 1). However, the lack of XIST activity
leads to the failed inactivation and duplication of the gene on the second X chromosome, resulting in
its activation [14,15].
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Another key lncRNA that mediates the X chromosome inactivation is TSIX. TSIX acts as a XIST 
repressor. TSIX is the antisense RNA of XIST and their differential expression patterns define the 
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and the nuclear matrix protein heterogeneous nuclear ribonucleoprotein U (hnRNPu) interact and, 
upon the depletion of hnRNPu, XIST is detached from the inactive X chromosome (Xi) and diffusely 
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upon the depletion of hnRNPu, XIST is detached from the inactive X chromosome (Xi) and diffusely
localized into the nucleoplasm [10,15].
Recent studies have shown that XIST has an aberrant expression pattern in breast cancer [16],
cervical squamous cell carcinoma [17], colorectal cancer [18], gastric cancer [19], glioma [20],
hepatocellular carcinoma [21], nasopharyngeal carcinoma [22], non-small cell lung cancer (NSCLC) [23],
pancreatic cancer [24], osteosarcoma [25], and ovarian cancer [26]. Furthermore, XIST was shown to
regulate tumour cell migration, proliferation, and invasion, in NSCLC [6,27]. Wang et al. showed that
cell lines and patient samples of NSCLC overexpressed XIST and shown that XIST knockdown inhibits
tumour growth in vivo. Moreover, XIST exhibits oncogenic properties by regulating the miR-449a and
B-cell lymphoma 2 (Bcl-2) gene in NSCLC [5]. The same study has shown that BRCA1 also influences
the concentration of XIST on the Xi. Specifically, RNAi of BRCA1 decreases the concentration of
XIST on Xi, and the reduction of BRCA1 by Cre-mediated excision also decreases XIST concentration
on Xi [28]. Collectively these data indicate that XIST could be an important novel biomarker for the
detection of NSCLC [23,29]. We hypothesize that there is a higher order of complexity in the regulation
of XIST and its impact in multiple signaling pathways. In this study, we investigate changes in the
transcriptional landscape of cell lines from male and female patients with NSCLC where XIST was
downregulated and studied the expression and correlation of associated genes in lung cancer.
2. Results
2.1. Expression Level of XIST, TSIX, hnRNPu, Bcl-2, and BRCA1 in NSCLC
Leveraging the available expression data from TCGA and GTEX, as tumour and respectively
normal control lung samples (referring as ‘Lung’ in figures), we have investigated differential expression
patterns of XIST, TSIX, hnRNPu, Bcl-2, and BRAC1 in lung adenocarcinoma (LUAD) and lung squamous
carcinoma (LUSC) (Supplementary Figure S1).
Overall, similar to previously published results where XIST is upregulated in various cancers [6,30],
we found a similar trend, in LUAD compared to normal lung cohort (LUNG), whereas in LUSC a
downregulation was observed (Figure 2a). However, given the involvement of XIST in X chromosome
inactivation, we dissected these data further by measuring the expression of XIST in males and females.
Here, a different picture emerges, suggesting a gender-specific downregulation in tumour samples
compared to control Figure 2b. For TSIX, a modest overall upregulation in LUAD was observed,
whereas in LUSC a significant downregulation when compared to normal lung (LUNG) was noted
(Figure 2c). Further gender stratification showed the emergence of a similar distribution as noted
earlier for XIST (Figure 2d).
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Next, we investigated the expression patterns of hnRNPu, Bcl-2, and BRCA1 in the same cohorts of
patients (Figure 3). Overall, we found that the expression of hnRNPu and BRCA1 in LUAD and LUSC
is significantly upregulated compared to the normal lung samples in both males and females. On the
other hand, Bcl-2 appears to be downregulated only in LUAD when compared to controls. Moreover,
the three genes did not display any gender-specific expression patterns as observed earlier for XIST and
TSIX suggesting that the transcriptional landscape of hnRNPu, Bcl-2, and BRCA1 is gender agnostic.
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Next, we investigated whether the XIST and the four associated genes have correlated expression
patterns in NSCLC (Supplementary Figure S3). For this, we used Spearman’s rank correlation tests
evaluating male and female samples individually. We found that XIST has an independent expression
pattern with respect to hnRNPu, Bcl-2, and BRCA1. However, as expected we observed a strong
correlation between XIST and TSIX expressions in samples derived from female patients (R = 0.75 for
LUNG cohort, 0.84 for LUAD and 0.89 for LUSC) (Figure 5).
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Figure 5. Cor lation wi h regression line for gene expression (in unit 2(norm_count + 1)) for XIST
vs. TSIX, Spearman’s rank correlation test was used to generate the correlation coefficient represented
as R in the analyses, p represents p-value. Healthy lung, LUAD, and LUSC were compared separately
in both sexes. Total sample number is 1299, 794 derived from male patients and 505 from female
patients. There are 116 samples from male patients with 0 expression in XIST, 461 in TSIX. In female
patients de iv d samples, 17 show z o xpr ssi n for TSIX gene. All samples with zero expression in
both genes were removed from the analysis.
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2.2. Functional Analysis
Following the sexual dimorphism of XIST, we investigated the change in the genome transcriptional
landscape A549 (derived from male patient) and H1975 (derived from female patient) NSCLC cell lines
upon silencing XIST using siRNA (Figure 6). The differential expressed genes were identified using
RNAseq analysis. The results are summarized in the Vulcan plots. Overall, we distinguished three
types of genes (Figure 6a). First, there are genes (shown in red) that show a statistically significant
(p-value < 10−4) differential transcription pattern, with a large absolute value of log2FoldChange > 2,
between the two analyzed conditions. Second, there are genes (seen in green) that show a moderately
significant change in expression (p-value < 0.05) and an absolute value of log2FoldChange > 2. Finally,
some genes do not show any significant change in the transcription levels between the analyzed states
(shown here in grey).Cancers 2020, 12, x 8 of 17 
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Overall, 944 genes were significantly dysregulated after the treatment with the siRNA XIST for the
A549 cell line. From those genes, the 683 were downregulated at p < 0.05, and 261 were highly-significantly
down-regulated at p < 5× 10−5. In the H1975, 751 genes were significantly dysregulated after the treatment
with the siRNA XIST. 536 genes were downregulated at p < 0.05 and 113 significantly down-regulated
p < 5× 10−5 with two genes to present and highly significant upregulation after the transfection. The DEGs
are presented as supplementary table. The two cell lines had 34 downregulated genes in common with
p < 0.05, 24 downregulated genes with p < 5 × 10−5, and one gene (RHOH) that was up-regulated in the
H1975 and down-regulated for the A549 (Figure 6b). Subsequent analysis of the differentially expressed
genes (DEGs) using FunRich revealed distinct biological processes for the two cell lines, including signal
transduction, cell communication, metabolism, and energy pathways (Figure 6c).
A summary of the top DEG in the A549 and H1975 cell lines respectively is shown in Figure 6d.
In both cell lines, XIST was downregulated in agreement with previous studies that siRNA was
used [6,27,31,32]. PROX1AS1 (antisense RNA) and RHOH (a negative regulator of cell growth and
survival) were markedly upregulated in H1975 cells in agreement with RNAseq data. We expanded on
these observations in A549 cells where RHOH, PRKCQ (required for the activation of the transcription
factors NF-kB and AP-1), NrCAM (required for normal responses to cell-cell contacts in the brain and
peripheral nervous system), and CDKN1A (involved in p53 mediated inhibition of cellular proliferation
to DNA damage) were downregulated in siRNA treated cells in agreement with the general trend
observed in RNAseq for this cell line (Figure 7).
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3. Discussion
In this study, we provide a novel insight into the expression of XIST and key co-expressed (?)
genes. Leveraging the available large-scale sequence data from TCGA and GTEX, we demonstrate that
XIST, TSIX, hnRNPu, Bcl-2, and BRCA1 are differentially expressed in two different types of lung cancer
when compared to controls. Initial observations suggested that XIST was significantly upregulated in
LUAD compared to controls. This finding corroborates previous studies where XIST has been shown
to be over-expressed in lung cancer and other cancers [23,31,33–37].
However, subsequent stratification by sex revealed that XIST is highly expressed in females and
downregulated in LUAD and LUSC when compared to normal controls. Although this might appear
as a discrepancy, it is evident that there is a vast range in XIST’s gene expression when all samples are
measured independently of gender. Thus, depending on data preparation and processing a potentially
different picture can emerge. For example, in all earlier studies, XIST expression was not stratified in
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male and female lung cancer patients and numbers were considerably lower to the ones assessed in
this study. Of note, our detailed analysis revealed the presence of two groups in control and LUAD
cohorts (Figure 3a). Apart from issues relating to sex-specific expression, the preparation of RNA and
subsequent analyses of data might also be contributing factors for the detection of lncRNAs. It has
been recommended -when using sequencing for lncRNAs- that rRNA depletion (instead of polyA
selection) should be performed [38]. If RNA-seq is polyA+ enriched, it will bias the analysis. It has
also been suggested that 50 million paired reads are needed for tissues, as there are so many and low
abundant lncRNAs. Another factor that can potentially induce different results is the method used for
the quantification of lncRNAs [39]. Our data provides a deeper insight into the differential expression
of XIST and highlights the need of standardization of RNA preparation protocols that would ultimately
increase the transcriptomic comparability between different RNA-seq datasets, thus enabling a better
mapping of lncRNAs [40,41].
Clustering of tumour and healthy lung samples in a 2D map using t-SNE algorithm based on
the normalized expression levels of XIST, TSIX, hnRNPu, Bcl-2, and BRCA1, revealed that collectively
these five genes -when assessed together- can have a diagnostic potential in both LUAD and LUSC.
This observation warrants further investigation in both tissue and liquid biopsies from NSCLC patients
using a much larger cohort especially for the healthy control group. Further, a strong correlation
between XIST and TSIX was seen. TSIX is the antisense of XIST. It is the complementary sequence
to XIST that is 40 kilobases long as is transcribed in the opposite direction across the XIST gene.
Much like XIST, TSIX only acts on the chromosome it is produced by. The relationship between TSIX
and XIST is inverse meaning that when the expression of TSIX is increased, XIST expression is reduced
therefore it blocks inactivation in the cis or same X chromosome. When TSIX expression is reduced,
XIST expression is increased and causes the inactivation of the X chromosome [4].
Silencing XIST in vitro resulted in 944 DEGs for A549 and 751 DEGs for H1975 cell lines respectively.
A common trend for both cell lines was that the majority of DEGs were downregulated compared to
controls, providing further evidence for a critical role of XIST in cell proliferation as it has been shown
in previous studies [6].
For example, in A549 cells, genes like protein kinase C theta (PRKCQ/PKC-θ), cyclin-dependent
kinase inhibitor 1A (CDKN1A/p21), neuro-glia-related cell-adhesion molecule (NrCAM) and ras
homolog family member H (RHOH) were amongst the most downregulated genes. PKC-θ enhances
anchorage-independent survival, growth-factor-independent proliferation, and migration and its
down-regulation enhances anoikis [42]. In addition PKC-θ regulates cell cycle checkpoint pathways
in lung cancer [43]. Cyclin-dependent kinase inhibitor 1A (p21) can exert multiple roles including
progression of the cell cycle, DNA repair, apoptosis, and can also function as an oncogene which
promoting tumour growth by inhibiting apoptosis. Furthermore, another role of p21 is that it can be
used as a predictive biomarker of response to therapy in TP53 and KRAS mutated NSCLC [44–46].
NrCAM is upregulated in a series of carcinomas like papillary thyroid carcinomas [47,48] and significant
overexpression of the NrCAM in SCLC was also noted in comparison to normal lungs [49]. Of note,
stable expression of the NrCAM ectodomain in NIH3T3 cells induced tumorigenesis in mice [50].
RHOH on the other hand, is a negative regulator of cell growth and survival. Rho GTPases regulate cell
migration, proliferation, survival, and death. All these cellular processes are crucial for the maintenance
of normal tissues, but also contribute to cancer progression [51]. For example, RHOH expression levels
correlate with prostate cancer progression [52].
In H1975 cells silencing XIST lead to a highly significant down-regulation of 113 genes. One of
these genes was MYC, a family of regulator genes and proto-oncogenes that code for transcription
factors. It is well known that c-myc oncogene is frequently amplified in lung tumours and has been
linked to their malignancy [53]. In a conditional model for the metastasis of NSCLC, c-myc played a
crucial role in this process [54], and is overexpressed in 40–75% of NSCLC cases [55]. Inhibiting MYC
on NSCLC in mice, lead to rapid regression of tumours with mild reversible side effects [56]. It is
possible therefore that MYC can be targeted via silencing XIST. In contrast to A549 cells, RHOH was
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upregulated in H1975 cells following downregulation of XIST. This warrants further research as it
might be a case of a differential expression in a cell- or sex-specific manner. Future studies should
involve further research into the role of XIST using a wider repertoire of in vitro models. Our current
cell lines have an EGFR mutant phenotype harbouring a T790M resistance mutation and a L858R
sensitizing mutation (H1975), whereas the A549 cell line is KRAS mutant. Of note, mutations of the
inactive X chromosome constitute a feature of tumorigenesis [57].
Gene enrichment analyses revealed that for A549 cells the main biological processes (in terms
of percentage of genes involved) are signal transduction, cell communication, energy pathways,
and metabolism; with the latter two having a number of same genes involved. For example, CYP24A1
has oncogenic properties in lung adenocarcinoma [58,59] and AKR1B10 has been shown to induce the
metastatic potential of lung cancer cells to the brain in vitro. MicroRNA-1304 inhibited the growth
of an NSCLC cell line by targeting HMOX1 [60]. Similarly, enrichment analysis in siRNA-treated
H1975 cells, revealed that a number of processes including cell communication and signal transduction.
These involve genes like MUC16 (CA125) whose levels relate to different stages of NSCLC [61],
and PTK7 that is associated with lymph node metastasis as well as ALK and EGFR mutations in lung
cancer [62]. In addition, PTN another gene effected by XIST is a heparin-binding growth factor that is
involved with tumour progression [63]. In the same cell line, XIST affected the expression of 13 different
zinc finger proteins. This is of increasing importance since they constitute the largest transcription
factor family in the human genome and have been implicated in cancer progression [64].
Collectively, our study raises issues regarding detection of lncRNA using RNA-seq and provides
a novel insight into a sex-specific role of XIST that warrants further investigation that can be of
translational value in terms of the development of biomarkers and new therapeutic approaches
targeting XIST and/or components of the signaling pathways it regulates in NSCLC.
4. Materials and Methods
4.1. Cell Lines
Two cell lines were used as in vitro models for lung cancer, A549 (ATCC® CCL-185™,
Gaithersburg, MD, USA) and H1975 (ATCC® CRL-5908™, Gaithersburg, MD, USA). A549 cells
were grown in complete DMEM (Dulbecco’s Modified Eagle’s Medium, Gibco, Fisher Scientific,
Loughborough, UK) with 10% fetal bovine serum (FBS, Gibco, Fisher Scientific, Loughborough, UK),
1% penicillin/streptomycin (Gibco, Fisher Scientific, Loughborough, UK) and 1% L-Glutamine
(Gibco, Fisher Scientific, Loughborough, UK). H1975 cells were grown in RPMI + 1% L-Glutamine
(Gibco, Fisher Scientific, Loughborough, UK), 10% FBS and 1% Pen/strep. Cell lines were cultured at
37◦C, in a 5% CO2 environment.
4.2. siRNA for XIST
We used siRNA targeted to XIST (SMARTpool: ON-TARGETplus, Dharmacon, CO, USA) to
suppress XIST gene expression in A549 and H1975 cells. Both cell lines were seeded at 2× 104 per well in
6-well plates. The siRNA transfection was carried out once at a concentration of 25 nmol/L per well/dish
using Dharmafect 1 transfection reagent and serum-free media, a scrambled control was also included
(ON-TARGETplus Non-targeting Pool; Horizon Discovery, UK). Cells were cultured in 3 biological
replicates for 48 and 72 h. Then, 24 h post-transfection the medium was changed and replaced with
fresh antibiotic-free medium [31].
4.3. RNA Isolation, cDNA Synthesis, and qPCR
RNA was extracted from cell lines, using the GenElute mRNA MiniPrep Kit (Merck, Feltham, UK),
a silica membrane/spin column method, and stored at −80 ◦C until further use. cDNA was synthesized
from mRNA using Superscript II (Fisher Scientific, Loughborough, UK). cDNA concentration was
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normalized using RNA concentrations determined by NanoDrop (Fisher Scientific, Loughborough, UK)
and was synthesized to a concentration of 1000 ng according to manufacturer’s instructions.
4.4. RT-qPCR
Relative expression of the genes of interest was assessed by quantitative PCR using the SYBR
green PCR master mix ROX (ABI, Fisher Scientific, Loughborough, UK) (Table 1). 18S RNA was used
as the endogenous control and the targets investigated were manufactured by Sigma-Aldrich. Then,
1 µL from the cDNA (1000 ng/mL) and 0.5 µL of the primers (10 µM) were used for each reaction.
All reactions were run in triplicate and a non-template control (NTC) was included in every run.




















qPCR data of relative gene expression was analyzed using the ∆∆Ct method whereby the endogenous control
Ct is subtracted from the gene of interest Ct to calculate ∆Ct, and a relative quantity value was calculated by
finding 2−∆∆Ct. A Student’s unpaired t-test was used to calculate statistical significance (p < 0.05).
4.5. RNAseq
RNA sequencing was carried out on lung cancer cell lines treated with siRNA XIST for 48 h.
All samples were sequenced at 75bp paired-end according to Illumina specifications. The data were
analyzed using open-source software from the Tuxedo suite. Reads were mapped to the human
reference genome hg19 using the GENCODE 24 annotations [6], with TopHat2 [23] (Bowtie 2) under
standard conditions. The alignments were filtered for high-quality hits with a minimum selection
threshold score of 30. The mapped reads were assembled into transcripts and quantified using the
Cufflinks package [34]. Functional enrichment analyses and Venn diagrams were performed in the
open software FunRich. The statistical cut-off of functional enrichment analyses using this stand-alone
software was kept at default setting with a p-value < 0.05 after Bonferroni correction.
4.6. Bioinformatic Analysis
The XIST expression data and associated sample survival information were extracted from the
UCSC Xenabrowser (xenabrowser.net), cohort “TCGA TARGET GTEx”. Samples from the publicly
available datasets from The Cancer Genome Atlas project (TCGA), and Genotype-Tissue Expression
project (GTEx) labelled as “primary tumour” and respectively “normal tissue” were selected for further
processing (Figure 8). All expression data were cross-study normalized by UCSC using TOIL [35].
All expression data is presented in units of log2(norm_count + 1). Disease-specific phenotype data
related to cancer stage, patient age, gender, and smoking status were extracted from the UCSC
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Xenabrowser TCGA Lung Adenocarcinoma (LUAD) and TCGA Lung Squamous Cell Carcinoma
(LUSC) cohorts.Cancers 2020, 12, x 13 of 17 
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5. Conclusions
Our study provides a novel insight into the role of XIST in lung cancer. Apart from exhibiting sexual
dimorphism in terms of expression, the downregulation of this lncRNA in NSCLC appears to influence
differential signalling cascades and genes in male versus female cancer cell lines. The co-expression of
XIST, TSIX, hnRNPu, Bcl-2, and BRCA1 provided a strong collective feature to discriminate between
controls and LC, implying a diagnostic potential.
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(c) XIST/BCL2, (d) XIST/BRCA1, (e) XIST/TSIX/HNRNPU, (f) XIST/HNRNPU/BCL2, (g) XIST/TSIX/BRCA1,
(h) XIST/TSIX/BCL2, (i) XIST/BCL2/BRCA1, (j) XIST/HNRNPU/BRCA1, (k) XIST/TSIX/HNRNPU/BRCA1,
(l) XIST/BCL2/BRCA1/HNRNPU, (m) XIST/TSIX/BCL2/BRCA1, (n) IST/TSIX/BCL2/HNRNPU. Figure S3:
Correlation with regression line for gene expression (in units if log2(norm_count + 1)) for all pairwise combinations
of genes from XIST, TSIX, hnRNPu, TSIX, Bcl-2 and BRCA1. Spearman’s rank correlation test was used to generate
the correlation coefficient represented as R in the graph, p represents p-value. Healthy lung, LUAD, and LUSC
were compared separately in both sexes. Total sample number is 1299, 794 derived from male patients and
505 from female patients. There are 116 samples from male patients with 0 expression in XIST, 461 in TSI ,
1 in hnRNPu, Bcl-2, and BRCA1. In female patients derived samples, 17 show zero expression fo TSIX gene.
Cancers 2020, 12, 3499 13 of 16
All samples with zero expression in both genes investigated were removed the analysis. Table S1: Spreadsheet
with the differentially expressed genes in A549 and H1975 cell lines following siRNA of XIST.
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